Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria
Halbroth BR., Sebastian S., Salman AM., Ulaszewska M., Gola A., Longley RJ., Janse CJ., Khan SM., Hill AVS., Spencer AJ.
Despite promising progress in malaria vaccine development in recent years, an efficacious subunit vaccine againstPlasmodium falciparumremains to be licensed and deployed. Cell-mediated protection from liver-stage malaria relies on a sufficient number of antigen-specific T cells reaching the liver during the time that parasites are present. A single vaccine expressing two antigens could potentially increase both the size and breadth of the antigen-specific response while halving vaccine production costs.